Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report published on Tuesday morning. The firm issued a buy rating on the stock.

Trinity Biotech Stock Performance

Trinity Biotech stock opened at $1.80 on Tuesday. The company has a 50-day simple moving average of $2.11 and a 200-day simple moving average of $2.29. The firm has a market capitalization of $13.72 million, a P/E ratio of -0.57 and a beta of 1.21. Trinity Biotech has a one year low of $1.79 and a one year high of $6.20.

Trinity Biotech (NASDAQ:TRIB) last released its quarterly earnings results on Wednesday, January 31st. The company reported ($0.90) EPS for the quarter. The firm had revenue of $14.68 million for the quarter. As a group, sell-side analysts forecast that Trinity Biotech will post -1.5 earnings per share for the current year.

Hedge Funds Weigh In On Trinity Biotech

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Atria Wealth Solutions Inc. grew its position in Trinity Biotech by 38.9% in the 4th quarter. Atria Wealth Solutions Inc. now owns 34,300 shares of the company’s stock valued at $34,000 after buying an additional 9,600 shares in the last quarter. Renaissance Technologies LLC grew its position in Trinity Biotech by 2.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,503,336 shares of the company’s stock valued at $1,842,000 after buying an additional 34,900 shares in the last quarter. Virtu Financial LLC bought a new position in Trinity Biotech in the 1st quarter valued at about $40,000. Finally, Whitefort Capital Management LP grew its position in Trinity Biotech by 1,067.8% in the 1st quarter. Whitefort Capital Management LP now owns 409,517 shares of the company’s stock valued at $434,000 after buying an additional 374,449 shares in the last quarter. Institutional investors own 78.97% of the company’s stock.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.